ライフサイエンスコーパス: group B Streptococcus

1 etence and survival following infection with group B Streptococcus.

2 cific role for IKKbeta during infection with group B streptococcus.

3 stinguishable clinically from that caused by group B streptococcus.

4 bacteria such as Listeria monocytogenes and group B streptococcus.

5 with a putative peptidoglycan hydrolase from group B streptococcus.

6 ccus aureus, Staphylococcus epidermidis, and group B Streptococcus.

7 hore A23187, nigericin, Candida albicans and Group B Streptococcus.

8 emic infection with the pathogenic bacterium group B Streptococcus.

9 sociated with lower incidence of early-onset group B streptococcus (0.23 per 1000 livebirths [95% CI

10 Incidence of early-onset group B streptococcus (0.43 per 1000 livebirths [95% CI

11 neumoniae, 1.1; Neisseria meningitidis, 0.6; group B streptococcus, 0.3; Listeria monocytogenes, 0.2;

12 open reading frame, spb1 (surface protein of group B streptococcus 1).

13 auses (2 influenza; 2 human herpesvirus 6; 2 group B Streptococcus; 2 Streptococcus pneumoniae; 1 HSV

14 itis, the predominant identified causes were group B streptococcus 25% (16-33), Streptococcus pneumon

15 li (16.3%), Enterococcus species (3.9%), and group B Streptococcus (3.1%).

16 Finally, we screened the array with group B Streptococcus, a major cause of neonatal meningi

17 The alpha C protein of group B streptococcus, a virulence determinant for this

18 s of murine and human macrophages induced by group B Streptococcus agalactiae (GBS) is likely an impo

19 Group B Streptococcus agalactiae bacteria (group B strep

20 Many group B Streptococcus agalactiae strains and other patho

21 tent cytokine response of blood monocytes to group B Streptococcus, although monocytes serve as the k

22 n endothelial cells show enhanced binding to group B Streptococcus and are more susceptible to apopto

23 Although decreased killing of group B streptococcus and H. influenzae was observed in

24 that nonopsonic recognition between type III group B streptococcus and human neutrophils would occur

25 4-kb foreign DNA element that is shared with group B Streptococcus and is present in all serotype M28

26 Several polysaccharides from group B Streptococcus and other bacterial species were s

27 Group B streptococcus and respiratory syncytial virus ar

28 maternal immunisation strategies to prevent group B streptococcus and respiratory syncytial virus in

29 hat is known about immune protection against group B streptococcus and respiratory syncytial virus, i

30 cell wall fragments from lysates of type III group B Streptococcus and showed that the complexes cont

31 reduced phagocytosis of bacteria, including group B streptococcus and Staphylococcus aureus.

32 red for capsule polymerization and export in group B Streptococcus and Streptococcus pneumoniae.

33 in 87.0% of the women who were positive for group B streptococcus and who delivered at term, but in

34 Cytomegalovirus, Escherichia coli, group B Streptococcus, and other infections contributed

35 ons with strains of the sialylated pathogen, group B Streptococcus, and with sialoglycans presented a

36 Nonpregnant adults with group B streptococcus bacteremia were identified by acti

37 The rate of screening for group B streptococcus before delivery increased from 48.

38 re born to women who had tested negative for group B streptococcus before delivery.

39 acrophage (MPhi) receptor in the response to group B Streptococcus, both in bone marrow-derived MPhis

40 monas aeruginosa, Staphylococcus aureus, and group B streptococcus by increasing membrane permeabilit

41 s derived from a wild-type strain of type Ia group B Streptococcus by selectively inactivating each g

42 The Group B Streptococcus capsular polysaccharide type IX wa

43 Type III group B Streptococcus capsular polysaccharide was linked

44 K1, groups W-135, Y, and C meningococci, and group B Streptococcus capsular polysaccharides modifies

45 capsular serogroup C (MenC) or Gram-positive group B Streptococcus, capsular type III (GBS-III) bacte

46 Group B Streptococcus causes a variety of morbid and som

47 ated polysaccharides supports a model of the group B Streptococcus cell surface in which the group B

48 ch 31, 2015, that reported the prevalence of group B streptococcus colonisation in pregnant women.

49 untry and regional heterogeneity in maternal group B streptococcus colonisation is unlikely to comple

50 We did a systematic review of maternal group B streptococcus colonisation studies by searching

51 he estimated mean prevalence of rectovaginal group B streptococcus colonisation was 17.9% (95% CI 16.

52 h enrichment culture method for detection of group B streptococcus colonization in pregnant women.

53 xtraction is a suitable method for detecting group B streptococcus colonization in pregnant women.

54 Group B Streptococcus colonization is frequent and dynam

55 The estimated average duration of any group B Streptococcus colonization was longer for women

56 culture method with the Gen-Probe AccuProbe Group B Streptococcus Culture Test (APGB) and the BD Gen

57 Group B Streptococcus detection directly from Copan ESwa

58 tion against both early-onset and late-onset group B streptococcus disease.

59 Routine screening for group B streptococcus during pregnancy prevents more cas

60 to accurately estimate the global burden of group B streptococcus, especially in low-income countrie

61 These results demonstrate that Group B Streptococcus expresses a specific ecto-5'-nucle

62 The exception was Streptococcus agalactiae (group B Streptococcus), for which non-contaminant signal

63 agar plate (SBAP) and AccuProbe detection of group B streptococcus from overnight LIM broth enhanceme

64 Group B Streptococcus (GBS) (150/302 [50%]; incidence, 0

65 e (n=5), or 2) choriodecidual inoculation of Group B Streptococcus (GBS) 1x10(6) colony forming units

66 The sialylated capsular polysaccharide of group B Streptococcus (GBS) also presents terminal Siaal

67 006, cross-reacts with serogrouping kits for group B Streptococcus (GBS) and could be misidentified i

68 defenses against the frequent human pathogen group B Streptococcus (GBS) and other extracellular bact

69 to inhibit growth and biofilm production in Group B Streptococcus (GBS) and Staphylococcus aureus.

70 e of the BBB to the human meningeal pathogen group B Streptococcus (GBS) and the organism's major vir

71 Infections such as group B Streptococcus (GBS) are an important cause of ma

72 nant monkeys (Macaca nemestrina) with either group B streptococcus (GBS) at 1 x 10(6) CFU (n = 5) or

73 rd most common cause of neonatal death, with Group B Streptococcus (GBS) being the leading bacterial

74 Group B Streptococcus (GBS) beta C protein elicits prote

75 We examined the virulence role of group B Streptococcus (GBS) beta-hemolysin/cytolysin (be

76 tinguish between the nine known serotypes of group B streptococcus (GBS) by classical antibody-antige

77 G-independent opsonophagocytosis of type III group B Streptococcus (GBS) by peripheral blood leukocyt

78 Group B Streptococcus (GBS) can be found to colonize abo

79 genitourinary tracts of pregnant women with group B Streptococcus (GBS) can result in vertical trans

80 Colonizing group B Streptococcus (GBS) capsular polysaccharide (CPS

81 Group B streptococcus (GBS) capsular serotypes are major

82 Group B Streptococcus (GBS) causes invasive infections i

83 Group B streptococcus (GBS) causes serious diseases in n

84 Group B Streptococcus (GBS) causes severe disease in neo

85 Group B Streptococcus (GBS) causes substantial morbidity

86 Group B Streptococcus (GBS) causes urinary tract infecti

87 Group B Streptococcus (GBS) colonizes mucosal surfaces o

88 Maternal immunization against group B streptococcus (GBS) could protect infants from i

89 Maternal immunization against Group B streptococcus (GBS) could protect infants from i

90 We compared five approaches for group B streptococcus (GBS) detection: three culture-bas

91 The rates of early-onset Group B Streptococcus (GBS) disease (EOGBS) have decline

92 rea to determine risk factors for late-onset group B streptococcus (GBS) disease (onset of disease or

93 ps in order to minimize the impact of infant group B streptococcus (GBS) disease in the United Kingdo

94 During the 1990s the focus of group B streptococcus (GBS) disease research has shifted

95 te substantial progress in the prevention of group B Streptococcus (GBS) disease with the introductio

96 with HIV are at increased risk for invasive group B streptococcus (GBS) disease.

97 ed infants are at increased risk of invasive Group B Streptococcus (GBS) disease; however, the reason

98 rs for Disease Control guidelines to prevent group B Streptococcus (GBS) early-onset sepsis (EOS) has

99 Pathogenic bacteria such as group B Streptococcus (GBS) express and secrete hyaluron

100 Group B Streptococcus (GBS) frequently colonizes pregnan

101 Group B Streptococcus (GBS) frequently colonizes the hum

102 Transmission of group B Streptococcus (GBS) from mothers to neonates dur

103 (GM-CSF) gene-targeted mice (GM-/-) cleared group B streptococcus (GBS) from the lungs more slowly t

104 mistry was utilised to covalently ligate the Group B Streptococcus (GBS) GBS67 protein antigen with t

105 By sequence analysis of available group B streptococcus (GBS) genomes, we discovered a con

106 Immunogenic vaccines against group B Streptococcus (GBS) have been created by couplin

107 nd universal screening of pregnant women for group B streptococcus (GBS) have further changed the epi

108 flight mass spectrometry (MALDI-TOF MS) for group B streptococcus (GBS) identification, we recovered

109 Group B streptococcus (GBS) imposes a major health threa

110 itive predictive values for the detection of group B Streptococcus (GBS) in 206 LIM enrichment broths

111 Group B streptococcus (GBS) induces apoptosis in macroph

112 Here, we show that Group B Streptococcus (GBS) induces IFN-beta production

113 Group B streptococcus (GBS) infection is a leading cause

114 The burden of non-invasive Group B Streptococcus (GBS) infections in adults is unkn

115 Meningitis was induced by injecting Group B Streptococcus (GBS) into the cisterna magnae of

116 Group B streptococcus (GBS) is a beta-hemolytic gram-pos

117 Group B Streptococcus (GBS) is a common cause of neonata

118 Group B streptococcus (GBS) is a common commensal of the

119 Group B Streptococcus (GBS) is a frequent agent of life-

120 Group B Streptococcus (GBS) is a leading cause of bacter

121 Group B Streptococcus (GBS) is a leading cause of invasi

122 Group B Streptococcus (GBS) is a leading cause of neonat

123 Group B Streptococcus (GBS) is a leading cause of neonat

124 The group B Streptococcus (GBS) is a leading cause of neonat

125 Group B streptococcus (GBS) is a leading cause of young

126 Group B streptococcus (GBS) is a leading neonatal pathog

127 Group B Streptococcus (GBS) is a major cause of bacteria

128 Group B Streptococcus (GBS) is a major cause of invasive

129 Group B streptococcus (GBS) is a major cause of neonatal

130 Group B Streptococcus (GBS) is a major cause of neonatal

131 Group B Streptococcus (GBS) is a major cause of newborn

132 Group B Streptococcus (GBS) is a major cause of pneumoni

133 The group B streptococcus (GBS) is a major cause of pneumoni

134 Maternal colonization with group B Streptococcus (GBS) is a risk factor for neonata

135 Group B Streptococcus (GBS) is an encapsulated, gram-pos

136 Infection by group B streptococcus (GBS) is an important cause of bac

137 Group B Streptococcus (GBS) is an important cause of inf

138 Group B Streptococcus (GBS) is an important cause of inv

139 Group B Streptococcus (GBS) is an important human bacter

140 The group B streptococcus (GBS) is an important human pathog

141 Group B streptococcus (GBS) is an important human pathog

142 Group B Streptococcus (GBS) is an important pathogen of

143 Group B Streptococcus (GBS) is an important perinatal pa

144 Gastrointestinal (GI) colonization with group B Streptococcus (GBS) is an important precursor to

145 Group B Streptococcus (GBS) is an opportunistic bacteria

146 Group B Streptococcus (GBS) is an opportunistic organism

147 The facultative anaerobe group B Streptococcus (GBS) is an opportunistic pathogen

148 Group B Streptococcus (GBS) is classified into nine sero

149 The process of human infection by group B Streptococcus (GBS) is complex and multifactoria

150 Group B Streptococcus (GBS) is currently the leading cau

151 Serotype IV group B Streptococcus (GBS) is emerging in Canada and th

152 Group B Streptococcus (GBS) is frequently carried in the

153 Group B Streptococcus (GBS) is major cause of invasive d

154 Group B Streptococcus (GBS) is one of the most common or

155 Genital tract carriage of group B streptococcus (GBS) is prevalent among adult wom

156 accharide (CPS) and some surface proteins by group B Streptococcus (GBS) is regulated by growth rate.

157 Streptococcus agalactiae or group B Streptococcus (GBS) is the cause of early- and l

158 Group B Streptococcus (GBS) is the foremost bacterial ca

159 Group B Streptococcus (GBS) is the leading cause of bact

160 Group B Streptococcus (GBS) is the leading cause of bact

161 Group B Streptococcus (GBS) is the leading cause of bact

162 Group B Streptococcus (GBS) is the leading cause of huma

163 Group B Streptococcus (GBS) is the leading cause of inva

164 Group B Streptococcus (GBS) is the leading cause of meni

165 Group B streptococcus (GBS) is the leading cause of neon

166 Group B Streptococcus (GBS) is the leading cause of neon

167 Group B Streptococcus (GBS) is the leading cause of neon

168 Group B Streptococcus (GBS) is the most common bacterium

169 Maternal rectovaginal colonization with group B Streptococcus (GBS) is the most common pathway f

170 99 nonpregnant adult Maryland residents with group B Streptococcus (GBS) isolated from a normally ste

171 , we studied the population structure of 102 group B Streptococcus (GBS) isolates prospectively sampl

172 Studies have suggested that group B Streptococcus (GBS) maternal rectovaginal coloni

173 Maternal vaccination against group B Streptococcus (GBS) might provide protection aga

174 nces of the AmpliVue, BD Max, and illumigene group B Streptococcus (GBS) nucleic acid amplification t

175 eceived choriodecidual inoculation of either group B Streptococcus (GBS) or saline (n = 5/group).

176 Group B Streptococcus (GBS) or Streptococcus agalactiae

177 Group B streptococcus (GBS) or Streptococcus agalactiae

178 Group B streptococcus (GBS) pili may enhance colonizatio

179 Licensure of a Group B streptococcus (GBS) polysaccharide-protein conju

180 Group B Streptococcus (GBS) remains a leading cause of n

181 Group B streptococcus (GBS) remains a major cause of mor

182 Group B streptococcus (GBS) remains the leading cause of

183 To determine whether 2 monovalent group B streptococcus (GBS) serotype II or III capsular

184 on of the human epithelial cell line A549 by group B streptococcus (GBS) serotype VIII strains were c

185 Maternal group B streptococcus (GBS) serotype-specific capsular a

186 We investigated the association between group B Streptococcus (GBS) serotype-specific capsular p

187 Group B streptococcus (GBS) serotypes causing neonatal d

188 report that neuD, a gene located within the Group B Streptococcus (GBS) Sia biosynthetic gene cluste

189 dies for molecular and serological typing of group B streptococcus (GBS) strains as part of DEVANI (D

190 Detection of group B Streptococcus (GBS) strains at various bacterial

191 Streptococcal pathogens, such as the group B streptococcus (GBS) Streptococcus agalactiae, ar

192 ansplacental antibody transfer specific to 8 group B Streptococcus (GBS) surface proteins among 81 HI

193 Serotypes of group B streptococcus (GBS) that cause urinary tract inf

194 Resistance of group B streptococcus (GBS) to antibiotics, particularly

195 occus aureus, we found the neonatal pathogen group B Streptococcus (GBS) to be remarkably resistant t

196 of immunoglobulin G (IgG) antibodies against group B streptococcus (GBS) type III polysaccharide (PS)

197 to study maternal transfer of antibody to a group B Streptococcus (GBS) type III polysaccharide-teta

198 level of maternal immunoglobulin (Ig) G anti-group B streptococcus (GBS) type III required to protect

199 Although rarely encountered, group B Streptococcus (GBS) types IV and VII have been i

200 Group B Streptococcus (GBS) types VI and VIII are preval

201 Serotype V group B Streptococcus (GBS) was first isolated from huma

202 Mutagenesis of group B streptococcus (GBS) with TnphoZ, a transposon de

203 acterial polysaccharide exotoxin produced by group B Streptococcus (GBS), also referred to as GBS tox

204 women who are rectovaginally colonized with group B Streptococcus (GBS), but the risk of EOGBS from

205 rate kinase (PGK), present on the surface of group B streptococcus (GBS), has previously been demonst

206 rst comprehensive estimates of the burden of group B Streptococcus (GBS), including invasive disease

207 Group B Streptococcus (GBS), is a leading cause of neona

208 Streptococcus agalactiae, or group B Streptococcus (GBS), is an important opportunist

209 pathogen Streptococcus agalactiae, known as group B Streptococcus (GBS), is the leading cause of bac

210 marily caused by Escherichia coli (E. coli), Group B Streptococcus (GBS), Listeria monocytogenes, Hae

211 , 7 produced at least 1 stool that contained group B Streptococcus (GBS), Serratia marcescens, or Esc

212 In infants, the mode of acquisition of CC17 group B Streptococcus (GBS), the hypervirulent clone res

213 Group B Streptococcus (GBS), the leading cause of neonat

214 nducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vacc

215 nital inhabitant and opportunistic pathogen, group B Streptococcus (GBS), when present at the time of

216 Here, we define Group B Streptococcus (GBS)-mediated activation of the N

217 accine target of the major neonatal pathogen group B Streptococcus (GBS).

218 SA-colonized women were less likely to carry group B streptococcus (GBS).

219 etween these families was first described in Group B Streptococcus (GBS).

220 ence factors in the important human pathogen group B Streptococcus (GBS).

221 nal vaccines against neonatal disease due to group B Streptococcus (GBS).

222 ons caused by the leading neonatal pathogen, group B streptococcus (GBS).

223 cause invasive disease in humans, including group B Streptococcus (GBS).

224 uence typing (MLST) system was developed for group B streptococcus (GBS).

225 he pathogens group A Streptococcus (GAS) and group B Streptococcus (GBS).

226 ctors associated with vaginal acquisition of group B Streptococcus (GBS).

227 the pathogenesis of septic shock induced by group B Streptococcus (GBS).

228 colonizers and potential pathogens, such as group B Streptococcus (GBS).

229 Group B streptococcus (GBS; Streptococcus agalactiae) in

230 es of serotype III Streptococcus agalactiae (group B streptococcus [GBS]) can be divided into three s

231 Streptococcus agalactiae (group B Streptococcus [GBS]) causes serious infections i

232 Streptococcus agalactiae (group B streptococcus [GBS]) colonizes the rectovaginal

233 zed 31 isolates of Streptococcus agalactiae (group B Streptococcus [GBS]) from several geographic loc

234 Streptococcus agalactiae (group B Streptococcus [GBS]) has not been described as a

235 Streptococcus agalactiae (group B streptococcus [GBS]) is a Gram-positive bacteriu

236 Streptococcus agalactiae (group B Streptococcus [GBS]) is a leading cause of neona

237 Streptococcus agalactiae (group B streptococcus [GBS]) is a leading cause of neona

238 tal infection with Streptococcus agalactiae (group B Streptococcus [GBS]) is a leading cause of sepsi

239 colonization with Streptococcus agalactiae (Group B Streptococcus [GBS]) is a precursor to chorioamn

240 Streptococcus agalactiae (group B Streptococcus [GBS]) is an important cause of in

241 Streptococcus agalactiae (group B Streptococcus [GBS]) is an important neonatal pa

242 Streptococcus agalactiae (group B Streptococcus [GBS]) remains a leading cause of

243 coli, E. faecalis, Streptococcus agalactiae (group B streptococcus [GBS]), or Streptococcus pyogenes

244 Streptococcus agalactiae (Group B Streptococcus, GBS) causes life-threatening infe

245 Streptococcus agalactiae (group B streptococcus, GBS) causes neonatal disease and

246 Streptococcus agalactiae (group B streptococcus, GBS) expresses either Srr1 or Srr

247 Streptococcus agalactiae (Group B Streptococcus, GBS) is a commensal of the digest

248 Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of invasi

249 Streptococcus agalactiae (group B Streptococcus, GBS) is the predominant cause of

250 Streptococcus agalactiae (group B Streptococcus; GBS) is a significant bacterial p

251 Streptococcus agalactiae (group B Streptococcus; GBS) produces a CPS that represen

252 -positive bacteria Streptococcus agalactiae (Group B Streptococcus; GBS) type III (GBSIII) and Strept

253 These include pneumococcus, group B Streptococcus, Haemophilus influenzae type b, an

254 of the CpsA protein of the zoonotic pathogen group B Streptococcus in capsule production and cell wal

255 Mean incidence of group B streptococcus in infants aged 0-89 days was 0.53

256 Group B streptococcus infection can be associated with i

257 ntibodies during the acute phase of invasive group B streptococcus infection in nonpregnant adults ma

258 more protective in a neonatal mouse model of group B Streptococcus infection than a vaccine construct

259 vival and conferred resistance to an in vivo group B streptococcus infection, we show that mice with

260 uggish mice displayed high susceptibility to group B streptococcus infection, with impaired TNF-alpha

261 ted aneurysms of visceral arteries caused by Group B streptococcus infection.

262 to the observed increase in dissemination of group B Streptococcus into the brain of Hs2st-deficient

263 The capsular polysaccharide of group B Streptococcus is a key virulence factor and an i

264 Group B streptococcus is a leading cause of serious infe

265 Group B streptococcus is a leading infectious cause of m

266 Any urine specimen with >=10(4) CFU/ml group B Streptococcus is significant for asymptomatic ba

267 Group B Streptococcus is the most common cause of bacter

268 Streptococcus agalactiae (Group B Streptococcus) is a commensal of the human intes

269 psonophagocytic killing of the corresponding group B streptococcus isolate in vitro.

270 by analysis of DNA band sizes of our control group B streptococcus isolate.

271 ive disease and the serotype distribution of group B streptococcus isolates.

272 & Microbe, Andrade et al. (2016) report that Group B Streptococcus limits type I IFN by expressing a

273 to understand these regional differences in group B streptococcus maternal colonisation and early-on

274 e concern that increasing efforts to prevent group B streptococcus neonatal disease may lead to an in

275 Streptococcus agalactiae (group B Streptococcus or GBS) is a common cause of invas

276 Streptococcus agalactiae (group B Streptococcus or GBS) is a common colonizer of t

277 -D-/-) and wild-type mice were infected with group B streptococcus or Haemophilus influenzae by intra

278 Streptococcus agalactiae (group B streptococcus, or GBS) is a common cause of bact

279 a 36.3-kb mobile genetic element of apparent group B Streptococcus origin, termed region of differenc

280 the protective response against the type III group B Streptococcus polysaccharide was comprised withi

281 The repeating units of the group B Streptococcus polysaccharides all contain an aci

282 d use of intrapartum antibiotic prophylaxis, group B streptococcus remains a leading cause of morbidi

283 ss several maternal immunisation initiatives-group B streptococcus, respiratory syncytial virus, pert

284 ment of the [D130A,S512A] mutant of SCP from group B Streptococcus (S. agalactiae, SCPB) revealed SCP

285 tions, poliovirus immunization schedule, and group B streptococcus screening and treatment.

286 eningococcal type C polysaccharide (MCPS) or group B Streptococcus serotype V (GBS-V) were unresponsi

287 Until recently, group B streptococcus, serotype V (GBS-V), was an infreq

288 ght and obesity increased the risk of EOS by group B Streptococcus, Staphylococcus aureus, and Escher

289 esponses to intact Pn14, isolated PPS14, and Group B Streptococcus (strain COH1-11) expressing capsul

290 In this report, we used a mutant strain of group B Streptococcus (Streptococcus agalactiae) type II

291 mologous gene from Streptococcus agalactiae (Group B Streptococcus), Streptococcus equi subsp. zooepi

292 F upon stimulation with Escherichia coli and group B Streptococcus, the leading pathogens of early-on

293 ning of pregnant women for colonization with group B streptococcus to identify candidates for intrapa

294 Group B streptococcus was the predominant pathogen among

295 n antiangiogenic polysaccharide derived from group B streptococcus, was administered by i.v. injectio

296 ed in the cytokine responses to infection by group B Streptococcus We focused on elucidating the func

297 Women with no documented culture for group B streptococcus were considered to have been cared

298 856 cases of group B streptococcus were identified in 2014-15, an inc

299 g cause of community-acquired pneumonia, and group B Streptococcus, which causes neonatal sepsis and

300 c.), a selective and differential medium for group B streptococcus, with culture using neomycin-nalid